The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Mezigdomide combinations show promising activity in relapsed/refractory multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses emerging data on mezigdomide-based therapy for relapsed/refractory multiple myeloma. He highlights encouraging efficacy and tolerability findings from clinical trials evaluating mezigdomide in combination with carfilzomib and dexamethasone, including activity in lenalidomide-refractory and difficult-to-treat patient populations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
